Tesamorelin

Overview

Tesamorelin is a synthetic Growth Hormone Releasing Hormone (GHRH) analog that was FDA-approved in 2010 under the brand name Egrifta for the treatment of HIV-associated lipodystrophy, specifically excess abdominal fat (visceral adipose tissue).

It remains one of the only FDA-approved peptides that directly stimulates growth hormone release, giving it a unique regulatory standing in the peptide landscape.

Key Characteristics

• Origin: Synthetic GHRH analog with trans-3-hexenoic acid modification
• Classification: Growth Hormone Releasing Hormone analog
• FDA Status: Approved for HIV lipodystrophy (Egrifta)
• Unique Feature: Selective visceral fat reduction
• Advantage: Preserves/increases lean mass while reducing fat

The Visceral Fat Problem

Visceral adipose tissue (VAT) is particularly dangerous:

• Surrounds internal organs
• Linked to cardiovascular disease
• Associated with insulin resistance
• Increases inflammatory markers
• More metabolically active than subcutaneous fat

Tesamorelin is one of few compounds shown to specifically target this dangerous fat depot.

Mechanism

Primary Mechanisms

1. GHRH Receptor Binding

Like other GHRH analogs, tesamorelin:

• Binds to GHRH receptors on pituitary somatotrophs
• Activates adenylyl cyclase pathway
• Increases cAMP
• Triggers GH release

2. Pulsatile GH Stimulation

Unlike synthetic GH:

• Maintains natural pulsatile secretion pattern
• Works with body's feedback systems
• Doesn't suppress endogenous production
• More physiological approach

3. IGF-1 Elevation

The released GH leads to:

• Hepatic IGF-1 production
• Systemic anabolic effects
• Lipolysis activation
• Protein synthesis enhancement

4. Targeted Lipolysis

Tesamorelin particularly affects visceral fat:

• Increases lipolysis in abdominal adipocytes
• Reduces trunk fat
• Preserves peripheral fat distribution
• May preferentially target VAT receptors

Research

HIV Lipodystrophy (FDA Approved)

CONFIRM & DEFINE Trials

Phase 3 trials demonstrated:

• 15-18% reduction in trunk fat at 26 weeks
• Maintained reduction with continued treatment
• Improved body image and patient satisfaction
• No worsening of glucose metabolism

Statistical Outcomes

• Trunk fat reduced by ~1 kg (15%)
• Visceral adipose tissue reduced by 15-17%
• Lean body mass preserved or increased
• Benefits maintained over 52+ weeks

Beyond HIV: Off-Label Research

General Visceral Fat Reduction

Studies in non-HIV populations suggest:

• Similar efficacy for VAT reduction
• Benefits for metabolic syndrome
• Potential cardiovascular risk reduction
• Improved insulin sensitivity

Cognitive Function (2025)

Emerging research indicates:

• Potential neuroprotective effects
• Improved cognitive scores in trials
• May benefit brain health via IGF-1
• Research ongoing in neurodegenerative disease

NAFLD/NASH

Non-alcoholic fatty liver disease studies show:

• Reduced liver fat content
• Improved liver enzymes
• Potential hepatoprotective effects
• Active area of research

Comparison to Other GH Therapies

Dosing

Research Protocols

Administration Notes

Timing

• Once daily, preferably at same time
• Can be morning or evening
• Some prefer pre-bed to mimic natural GH rhythm
• Empty stomach enhances absorption

Injection Technique

• Subcutaneous injection (abdomen preferred)
• Rotate injection sites
• Avoid areas of lipodystrophy
• Room temperature medication before injecting

Long-Term Use

• FDA trials extended to 52+ weeks
• Discontinuation leads to gradual return of fat
• Consider cycling to maintain sensitivity
• Monitor IGF-1 levels periodically

Reconstitution

• Comes as lyophilized powder
• Mix with provided diluent (0.4% carboxymethylcellulose sterile water)
• Roll vial gently - do not shake
• Use immediately after mixing (Egrifta)
• Research preparations: use bacteriostatic water, refrigerate

Pharmacokinetics

Absorption

• Subcutaneous: Rapid absorption
• Peak GH levels: 15-45 minutes
• Bioavailability: High

Distribution

• Acts primarily at pituitary
• Systemic effects through GH/IGF-1
• Does not accumulate

Metabolism

• Metabolized by peptidases
• Trans-hexenoic acid modification provides stability
• No CYP450 interactions

Elimination

• Half-life: 26-38 minutes (peptide)
• GH effects last several hours
• Daily dosing maintains effects

Safety

Known Side Effects

Common (>5%)

• Injection site reactions (erythema, pruritus)
• Arthralgia (joint pain)
• Peripheral edema
• Paresthesias (tingling)
• Myalgia (muscle pain)

Less Common (1-5%)

• Carpal tunnel syndrome
• Headache
• Nausea
• Skin rash

Generally Well-Tolerated

• Side effects often mild and transient
• Many resolve with continued use
• Dose reduction can help

Contraindications

Absolute Contraindications:

• Disruption of hypothalamic-pituitary axis (tumor, surgery, radiation)
• Active malignancy
• Pregnancy
• Hypersensitivity to tesamorelin or mannitol

Relative Contraindications:

• History of malignancy
• Diabetic retinopathy
• Uncontrolled diabetes

Drug Interactions

Monitor closely with:

• Diabetes medications (may affect glucose)
• Cortisol replacement therapy
• Other GH secretagogues

Generally safe with:

• HIV antiretroviral medications
• Most common medications

Monitoring

Baseline Assessments

• IGF-1 level
• Fasting glucose and HbA1c
• Lipid panel
• Body composition (DEXA if available)
• CT scan for visceral fat (clinical studies)

During Treatment

• IGF-1 every 3-6 months
• Fasting glucose periodically
• Body measurements/composition
• Side effect assessment

Long-Term Monitoring

• Annual malignancy screening
• Continued metabolic monitoring
• Treatment efficacy assessment

Regulatory

Current Status

Legal Considerations

• Prescription medication in approved indications
• Off-label prescribing legally permitted
• Insurance coverage limited to HIV lipodystrophy
• Research chemical versions available

Clinical Outlook

Tesamorelin has significant potential beyond HIV:

• Studies ongoing for general obesity
• NAFLD/NASH potential indication
• Cognitive benefits being explored
• May see expanded FDA indications
• Growing use in longevity medicine

References